Skip to main content

Advertisement

SpringerLink
Log in

Myc-oncogene Inactivating Effect by Proline Rich Polypeptide (PRP-1) in Chondrosarcoma JJ012 Cells

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

Proline rich polypeptide (PRP-1) produced by NPV and NSO cells is released into the general circulation and exerts its effect on the activity of immunocompetent and neuronal cells. PRP-1 is a unique regulator of hematopoiesis, stimulator of bone-marrow hematogenesis. Taking into consideration our preliminary data on antitumor and unique diverse biological properties of PRP-1 previously described by Galoyan et al., we proceeded with investigation of the PRP-1 effect on chondrosarcoma, the second most common malignancy in bone, which tends to be locally invasive and then metastatic. Currently it does not have any effective treatment and does not respond either to radiation or chemotherapy, leaving surgical resection as the only option. Our experimental results of PRP-1 action on human chondrosarcoma JJ012 cells demonstrated inactivation, abolishment of Myc oncogene activity usually upregulated in chondrosarcoma cells and other malignancies. The fact that addition of PRP-1 caused drastic inactivation of Myc–luc response element to the control level in human chondrosarcoma JJ012 cell line prompts to investigate further this neuropeptides powerful antioncogenic potential, opening up possibilities to consider PRP-1 as a potential therapeutic tool for chondrosarcoma treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Galoyan AA (2004) Brain neurosecretory cytokines: immune response and neuronal survival. Kluwer Academic/Plenum Publishers, NY

    Google Scholar 

  2. Galoyan AA (2008) The brain immune system: chemistry and biology of the signal molecules. In: Galoyan A, Besedovsky H (eds) Handbook of neurochemistry and molecular neurobiology, v.Neuroimmunology, Chap. 7, pp 155–195

  3. Galoyan AA, Grigorian SL, Badalyan ChV (2006) Treatment and prophylaxis of anthrax by brain neurosecretory cytokines. Neurochem Res 31(6):795–803

    Article  PubMed  CAS  Google Scholar 

  4. Galoyan AA, Sarkissian JS, Chavushyan VA et al (2005) Neuroprotective action of hypothalamic peptide PRP-1 at various time survival following spinal cord hemisection. Neurochem Res 30(4):507–525

    Article  PubMed  CAS  Google Scholar 

  5. Galoyan AA (2000) Neurochemistry of brain neuroendocrine immune system: signal molecules. Neurochem Res 25(9/10):1343–1355

    Article  PubMed  CAS  Google Scholar 

  6. Galoyan AA, Aprikyan VS (2002) A new hypothalamic polypeptide is a regulator of myelopoiesis. Neurochem Res 27(4):305–312

    Article  PubMed  CAS  Google Scholar 

  7. Galoyan AA, Shirvanian AJu (2006) Patent N 1696 A

  8. Simonyan GM, Nersesyan AK, Simonyan RM, Babayan MA, Simonyan MA, Galoyan AA (2005) Antitumor and antistressor effects of hypothalamic proline rich peptide (PRP-1) in sarcoma 45; possible biochemical mechanisms. Neurochemistry (RAS and NAS RA) 22(2):125–130

    Google Scholar 

  9. Galoyan AA, Shakhlamov VA, Kondakova LI, Altukhova VI, Polyakova GP (2001) The influence of proline-rich polypeptide on the morphology and mitotic activity of neurinoma Hassel node of tumor cells at rats (electron microscopic investigations). PNAS (Russian Academy of Sciences) 101(2):279–286

    Google Scholar 

  10. Galoyan AA, Shakhlamov VA, Malaytsev VV (2001) Changes in tumor cells L929 under PRP effect in vitro. Med Sci Armenia 41(1):25–29

    Google Scholar 

  11. Mirra J (1989) In: Lea and Febiger, bone tumors. Philadelphia

  12. Frassica FJ, Unni KK, Beabout JW, Sim FH (1986) Dedifferentiated chondrosarcoma. A report of the clinicophathological features and treatment of seventy-eight cases. J Bone Joint Surg Am 68:1197–1205

    PubMed  CAS  Google Scholar 

  13. Scully SP, Berend KR, Toth A, Qi WN, Qi Z, Block JA (2000) Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. Clin Orthop Relat Res 376:291–303

    Article  PubMed  Google Scholar 

  14. Galoian KA, Garamszegi N, Garamszegi SP, Scully SP (2007) Molecular mechanism of tenascin-C action on matrix metalloproteinase-1 invasive potential. Exp Biol Med 232(4):515–522

    CAS  Google Scholar 

  15. Fong YC, Yang WH, Hsu SF, Hsu HC, Tseng KF, Hsu CJ, Lee CY, Scully SP (2007) Methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. Orthop Res 25(8):1106–1114

    Article  CAS  Google Scholar 

  16. Sherf BA (1996) Dual luciferase reporter assay: an advanced coreporter technology integrating firefly and renilla luciferase assays. Promega Notes 57:2–9

    Google Scholar 

  17. Schally AV, Cumaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos (2001) Front Neuroendocrinol 22:248–291

    Article  PubMed  CAS  Google Scholar 

  18. Shachaf CM, Felsher DW (2005) Tumor dormancy and Myc inactivation: pushing cancer to the brink of Normalcy. Cancer Res 65:4471–4474

    Article  PubMed  CAS  Google Scholar 

  19. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235–248

    Article  PubMed  CAS  Google Scholar 

  20. Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042

    Article  PubMed  CAS  Google Scholar 

  21. Driker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

    Article  Google Scholar 

  22. Felsher DW, Nicole Bradon (2003) Pharmacological Inactivation of MYC for the treatment of cancer. Drug News Perspect 16(6):370–374

    Article  PubMed  CAS  Google Scholar 

  23. Felsher DW (2003) Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 3:375–378

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedics, Miller School of Medicine, University of Miami, 1600 NW 10th Ave, Suite 8006 (r-2), Miami, FL, 33136, USA

    Karina Galoian

  2. Department of Orthopedics, Miller School of Medicine, University of Miami Hospital, 1400 NW 12 Ave, Suite 2, Miami, FL, 33136, USA

    Sean Scully

  3. Institute of Biochemistry, National Academy of Sciences, 5/1 Paruir Sevak Str., Yerevan, 0014, Republic of Armenia

    Armen Galoyan

Authors
  1. Karina Galoian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean Scully
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Armen Galoyan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karina Galoian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galoian, K., Scully, S. & Galoyan, A. Myc-oncogene Inactivating Effect by Proline Rich Polypeptide (PRP-1) in Chondrosarcoma JJ012 Cells. Neurochem Res 34, 379–385 (2009). https://doi.org/10.1007/s11064-008-9794-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-008-9794-6

Keywords

Search

Navigation